Detailed information on the size of ice-nucleating particles (INPs) may be useful in source identification, modeling their transport in the atmosphere to improve climate predictions, and determining how effectively or ineffectively instrumentation used for quantifying INPs in the atmosphere captures the full INP population. In this study we report immersion-mode INP number concentrations as a function of size at six ground sites in North America and one in Europe using the micro-orifice uniform-deposit impactor droplet freezing technique (MOUDI-DFT), which combines particle size-segregation by inertial impaction and a microscope-based immersion freezing apparatus. The lowest INP number concentrations were observed at Arctic and alpine locations and the highest at suburban and agricultural locations, consistent with previous studies of INP concentrations in similar environments. We found that 91 ± 9, 79 ± 17, and 63 ± 21 % of INPs had an aerodynamic diameter > 1 µm at ice activation temperatures of −15, −20, and −25 °C, respectively, when averaging over all sampling locations. In addition, 62 ± 20, 55 ± 18, and 42 ± 17 % of INPs were in the coarse mode (> 2.5 µm) at ice activation temperatures of −15, −20, and −25 °C, respectively, when averaging over all sampling locations. These results are consistent with six out of the nine studies in the literature that have focused on the size distribution of INPs in the atmosphere. Taken together, these findings strongly suggest that supermicron and coarse-mode aerosol particles are a significant component of the INP population in many different ground-level environments. Further size-resolved studies of INPs as a function of altitude are required since the size distribution of INPs may be different at high altitudes due to size-dependent removal processes of atmospheric particles.

While many classes of chemotherapeutic agents exist to treat solid tumors, few can generate a lasting response without substantial off-target toxicity despite significant scientific advancements and investments. In this review, the paths of development for nanoparticles, oncolytic viruses, and oncolytic bacteria over the last 20 years of research towards clinical translation and acceptance as novel cancer therapeutics are compared. Novel nanoparticle, oncolytic virus, and oncolytic bacteria therapies all start with a common goal of accomplishing therapeutic drug activity or delivery to a specific site while avoiding off-target effects, with overlapping methodology between all three modalities. Indeed, the degree of overlap is substantial enough that breakthroughs in one therapeutic could have considerable implications on the progression of the other two. Each oncotherapeutic modality has accomplished clinical translation, successfully overcoming the potential pitfalls promising therapeutics face. However, once studies enter clinical trials, the data all but disappears, leaving pre-clinical researchers largely in the dark. Overall, the creativity, flexibility, and innovation of these modalities for solid tumor treatments are greatly encouraging, and usher in a new age of pharmaceutical development.

Primary biological aerosol particles (PBAPs) may impact human health and aerosol-cloud-climate interactions. The role of PBAPs in the earth system is associated with large uncertainties, for example of source estimates and the atmospheric lifetime. We used a chemistry-climate model to simulate PBAPs in the atmosphere including bacteria and fungal spores. Three fungal spore emission parameterizations have been evaluated against an updated set of spore counts synthesized from observations reported in the literature. The comparison indicates an optimal fit for the emission parameterization proposed by Heald and Spracklen (2009) and adapted by Hoose et al. (2010) for particle sizes of 5 µm or 3 µm, although the model still overpredicts PBAP concentrations in some locations. The correlations between the spore count observations and meteorological parameters simulated by the model show a strong dependence on the leaf area index in non-urban areas and the specific humidity in urban areas. Additional evaluation was performed by comparing our combined bacteria and fungal spore simulations to a global dataset of fluorescent biological aerosol particle (FBAP) concentrations. The model predicts the total sum of measured PBAP concentrations relatively well, typically within a factor of two of FBAP. Further, the modeled fungal spore results deviate from the FBAP concentrations when used as a rough proxy for spores, depending on the particle size used in the parametrization. Uncertainties related to technical aspects of the FBAP and direct-counting spore measurements challenge the ability to further refine quantitative comparison on this scale. Additional long-term data of better quality are needed to improve emission parameterizations.